Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. - Wikidata - awgldk - TriplyDB

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

http://www.wikidata.org/entity/Q35758267

about

Analysis of recent papers in hypertension: nighttime administration of at least one antihypertensive medication is associated with better blood pressure control and cardiovascular outcomes in patients with type 2 diabetes or chronic kidney disease Neurological complications in chronic kidney disease patients.Current issues in the management and monitoring of hypertension in chronic kidney disease.Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial.Nephropathy in youth and young adults with type 2 diabetes Blood pressure measurement: clinic, home, ambulatory, and beyond Reversed dipper blood-pressure pattern is closely related to severe renal and cardiovascular damage in patients with chronic kidney disease.A young patient with a family history of hypertension.Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU Management of hypertension in CKD: beyond the guidelines.Endothelial function in postmenopausal women with nighttime systolic hypertension.The complex relationship between CKD and ambulatory blood pressure patterns.Taking blood pressure-lowering medications at night.Ethical complexities in standard of care randomized trials: A case study of morning versus nighttime dosing of blood pressure drugs Targets, trafficking, and timing of cardiac autophagy A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone.Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease Nighttime BP in Elderly Individuals with Prediabetes/Diabetes with and without CKD: The HEIJO-KYO Study.Hypertension in chronic kidney disease: role of ambulatory blood pressure monitoring.Blood pressure measurement in peritoneal dialysis: which method is best?Efficacies of Controlling Morning Blood Pressure and Protecting the Kidneys by Treatment With Valsartan and Nifedipine CR or Valsartan and Amlodipine (MONICA Study)The association of night-time systolic blood pressure with ultrasound markers of subclinical cardiac and vascular disease.Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time?Hypertension and chronic kidney disease progression: why the suboptimal outcomes?Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation.Ambulatory blood pressure monitoring: recent evidence and clinical pharmacy applications.Pharmacologic treatment of hypertension in patients with chronic kidney disease.Ambulatory blood pressure in chronic kidney disease.Chronotherapy improves blood pressure control and reduces vascular risk in CKD.Epidemiology, prognosis, and treatment of resistant hypertension.Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders.Sleep-time ambulatory blood pressure as a novel therapeutic target for cardiovascular risk reduction.Circadian glomerular function: from physiology to molecular and therapeutical aspects.Treatment strategies to prevent renal damage in hypertensive children.Around-the-clock ambulatory blood pressure monitoring is required to properly diagnose resistant hypertension and assess associated vascular risk.Current therapeutic approaches to cardio-protection in hypertension.Treatment of hypertension with chronotherapy: is it time of drug administration?An Integrated View of Potassium Homeostasis.

P2860

Q27008919-97D72027-61F6-40BB-8F92-AADB0C7F7180 Q30252095-600727E0-4230-4608-A87C-46237087F5A6 Q33858915-2A8A4502-C920-4765-AF40-E1E5FA7F16B2 Q33881994-A3D1E0CA-9DC8-48A6-B47A-5AA258A36F73 Q33903763-AE28F1DD-1A59-40B5-A60E-5693B69EB252 Q34026662-23DD0DAE-F619-40C1-8E83-31A781DDFCAC Q34580946-29B63C31-324A-486D-9344-1F3ED2E7CA55 Q34629700-722094EB-7A8F-4A76-BCDF-3B69A8BAAAF8 Q35013404-4454C665-3BC5-4472-9D33-CFAC4225A82B Q35651663-1F0E7122-8FE3-4970-835B-E0B4DD9EA5E8 Q35822959-E4CBE12F-59DD-42A1-B4A1-9A16A11DBF6E Q36100474-DC89857E-A7C5-4002-BEE5-33E22442D328 Q36229558-36A0EC24-99F9-41F8-8E53-AEC5955410E2 Q36275898-76038583-39F1-4150-A773-2FF2A855E98D Q36413143-6ABBF574-FE85-4F77-AA28-E32A221874B2 Q36470706-138D1177-3CCF-42FF-907C-E076CE51DF6D Q36514370-A75889B8-20EE-4AC8-91EF-FF5EC21211B8 Q36602978-CD381B36-A838-4F0E-AA85-1F710306EC43 Q36675029-01E34E21-FE40-443A-B5B3-C042457EA9A8 Q36874538-2FC17656-CD2B-4AC8-8684-147496280AAE Q37025136-59D233CB-BF0E-4BBB-915A-2634B232749F Q37232295-3027B1B4-AA30-4DE3-BA8D-93ED630B146D Q37255216-38611641-56AD-407B-A53F-15784D6F91C6 Q37558264-718F6FAA-2163-4F77-A705-710527E23321 Q37616714-D078C45B-8C42-41B2-9E30-6AF82F9BA056 Q37618602-0D62C835-2F5D-4B4B-8D18-2BBF22B46B5C Q38053166-9FC21542-E37E-4AD1-9707-AC49B7DE6F15 Q38073206-F158AB06-D2FD-4318-B0C6-6D5A0A1E9948 Q38095805-66095216-B428-4CEF-A99E-2BEF7BCF9EDE Q38099767-BE7AF8B4-09D1-47C6-8F39-9F1A53CCBA6F Q38100986-64F3891C-A63B-4138-97A2-23228092DF94 Q38110711-A8F10B16-8BA6-44A4-B2A3-D0CED4E5FDF0 Q38177166-5A8087FC-C96F-4893-BAD8-D9A59E01D696 Q38185598-457A9DF3-825A-4659-98E5-1AD472B0BEC1 Q38187106-FFBE9A3A-560A-44B4-B591-061B8807A1DB Q38187597-55D4E46C-9B62-4E83-9540-69B795D9AF6B Q38208966-2FFCEE0A-B1AA-4B52-AA91-E049B6A42E74 Q38223595-E4BB3118-5C73-4B7B-807B-73353B7F102A Q38291112-7623E38C-3F51-4DFE-888D-2C4D6465D03B Q38541552-F3B45A6B-2D58-469F-B9E6-0BC6F1C98B6A

P2860

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

http://www.wikidata.org/entity/Q35758267

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

@ast

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

@en

type

label

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

@ast

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

@en

prefLabel

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

@ast

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

@en

P1433

Q35758267-9D07C5D4-AF1B-4CA7-8FB6-A5E395261A8E

P1476

Q35758267-3FA15A9D-E57C-49AE-BE57-93D04BDE68A7

P2093

Q35758267-65DE8DDB-CB12-402E-9249-D2F944B9668F

Q35758267-77C90BA3-263C-4551-BE18-097241B943D9

Q35758267-9817E574-39A3-41D8-9527-A249C5252D46

Q35758267-DF8C7643-EB43-4DFA-8DD4-0132E950EB61

P2860

Q35758267-12CE6ED4-DBBF-41BE-A2BF-902169D23C0E

Q35758267-247FCA01-1E8C-432F-85CE-8C754F0B520E

Q35758267-4A38FF4B-9192-42C8-994A-5B3FA6876BA2

Q35758267-5D4E547D-2EB6-4F03-AEB3-2A66441958E9

Q35758267-636CA2C6-467B-4DC7-A4CE-64A166BECE1F

Q35758267-6D0844E9-5521-484D-B198-EE8CBB19AA15

Q35758267-7BE94B31-6094-40ED-86D1-FB139CD0DF65

Q35758267-7F0AF829-3DEB-43FF-9C70-21C819550C85

Q35758267-8641C6C8-B5DA-43BE-9C21-08E5B91130A7

Q35758267-8CF1A869-B8E4-44FD-932B-F522C9C99BCE

P304

Q35758267-E56287C7-BF87-45F1-AEFD-CE988B07A583

P31

Q35758267-F981B2A5-04FB-4364-B0D2-56D7A9AC3E37

P356

Q35758267-A51ED60C-E02B-42B4-97C9-007E04BCB11A

P433

Q35758267-5DAE7577-D1B5-48CE-A6A0-50F522CED9A5

P478

Q35758267-8353AFDA-5DE2-4A1B-BAB3-14D376C554D0

P577

Q35758267-4242195C-12B2-45A7-B4B7-5463C322C5A2

P698

Q35758267-83D63AD8-E31A-41B2-929E-C80239CCC84C

P921

Q35758267-C573CB87-DCEC-42B2-99B9-BF8F51962548

P932

Q35758267-0DA4A67E-4B3A-499B-9E2B-5E1C969C1B9B

P356

P1433

Journal of the American Society of Nephrology

P1476

Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.

@en

P2093

Artemio Mojón

http://www.w3.org/2001/XMLSchema#string

Diana E Ayala

http://www.w3.org/2001/XMLSchema#string

José R Fernández

http://www.w3.org/2001/XMLSchema#string

Ramón C Hermida

http://www.w3.org/2001/XMLSchema#string

P2860

Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Intensive blood-pressure control in hypertensive chronic kidney disease

Out-of-office blood pressure monitoring in chronic kidney disease.

Administration-time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension.

Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications.

Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension.

P304

2313-2321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2011040361

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22025630

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3279936

http://www.w3.org/2001/XMLSchema#string